N4BP3 Inhibitors
N4BP3 inhibitors encompass a variety of chemical compounds that interact with signaling pathways to which N4BP3 is functionally connected, ultimately leading to its inhibition. Compounds that target the EGFR or HER2/neu receptors, for instance, result in reduced PI3K/AKT pathway activity, a crucial signaling route for N4BP3 function. The inhibition of PI3K itself, or the blockade of AKT phosphorylation, further attenuates this pathway, thereby indirectly decreasing the activity of N4BP3 by limiting the necessary signaling for its activity. Similarly, inhibition of mTOR, through compounds that target mTORC1, reduces downstream PI3K/AKT/mTOR signaling, which impacts N4BP3 due to its role in this pathway network. Additionally, cell cycle progression disruption via CDK4/6 inhibition indirectly affects N4BP3, highlighting the interconnectedness of cell cycle regulation and PI3K/AKT signaling.
The modulation of signaling cascades by these chemical inhibitors extends to other pathways that are linked to N4BP3 function. For example, kinase inhibitors that affect RAF and MEK enzymes lead to the downregulation of the MAPK/ERK pathway, which is also known to interface with pathways involving N4BP3, resulting in the protein's decreased activity. JNK pathway inhibition contributes to this multifaceted approach to inhibiting N4BP3 by altering signaling routes that are anticipated to intersect with those modulated by N4BP3. Furthermore, Src family kinase inhibition through certain compounds also causes changes in a variety of signaling pathways, including those associated with N4BP3, leading to an overall reduction in N4BP3 activity. This indicates that N4BP3 may not only be a downstream effector within these pathways but could also play a regulatory role, as its activity is sensitive to the status of these signaling networks.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
An EGFR inhibitor that leads to a reduction in PI3K/AKT signaling, a pathway that N4BP3 is known to interact with, resulting in decreased N4BP3 activity due to lessened downstream signaling. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Targets the HER2/neu and EGFR pathways, leading to diminished PI3K/AKT pathway activity which N4BP3 modulates, thereby reducing the functional activity of N4BP3 through indirect suppression of its signaling interactions. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor that blocks the PI3K/AKT pathway, one of the pathways N4BP3 is involved in, leading to decreased AKT phosphorylation and subsequent reduced activity of downstream effectors including N4BP3. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that attenuates the PI3K/AKT pathway, thereby indirectly inhibiting the function of N4BP3 by reducing the necessary PI3K signaling for its full activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that disrupts the mTORC1 pathway, which is connected to the PI3K/AKT pathway that N4BP3 engages with, ultimately leading to decreased N4BP3 activity due to inhibited downstream signaling. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
A CDK4/6 inhibitor that disrupts cell cycle progression, indirectly affecting the PI3K/AKT pathway and thereby inhibiting N4BP3 which is dependent on the proper functioning of this pathway for its activity. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Inhibits mTORC1, leading to decreased PI3K/AKT/mTOR signaling and thereby reducing the activity of downstream proteins such as N4BP3 which is part of this signaling network. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Specifically inhibits AKT phosphorylation, thereby hindering the PI3K/AKT/mTOR pathway and indirectly leading to the inhibition of N4BP3 activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
A multikinase inhibitor that targets RAF kinases, among others, leading to downregulation of the MAPK/ERK pathway and consequently impacting the activity of N4BP3 through reduced signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Specifically inhibits MEK1/2, leading to downregulation of the MAPK/ERK pathway, which is interconnected with pathways involving N4BP3, resulting in decreased N4BP3 activity. | ||||||